Physician profile
James Brian Davis
NPI 1245326461
$10,063.78
in general payments reported to CMS, 2019-2025
22 companies · $440 in 2025
The $440 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $239 · 2021: $605 · 2022: $955 · 2023: $6,623 · 2024: $649 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,625 · Food and Beverage: $2,229 · Travel and Lodging: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,625.00 |
| Food and Beverage | $2,228.85 |
| Travel and Lodging | $857.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $6,658.94 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $790.26 | 2019-2024 | Jornay Pm |
| Corium, LLC | $765.23 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $267.29 | 2019-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $220.65 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Adlon Therapeutics L.P. | $196.85 | 2019-2021 | |
| Stryker Corporation | $172.34 | 2022-2025 | Viaflow, Citrefix, Augment Injectable |
| Tris Pharma INC | $170.14 | 2019-2025 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $124.42 | 2019-2025 | Relexxii |
| Cranial Technologies, INC | $111.00 | 2019-2024 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $104.08 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $100.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.33 | 2019 | |
| W. L. Gore & Associates, INC. | $64.94 | 2021-2025 | Gore Cardioform Asd Occluder |
| Collegium Pharmaceutical, INC. | $55.54 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $45.69 | 2022-2024 | |
| Shire North American Group INC | $26.69 | 2019 | |
| Roche Diagnostics Corporation | $26.25 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.51 | 2024 | Ycanth |
| Seqirus USA INC | $17.83 | 2022 | |
| Averitas Pharma INC. | $16.86 | 2024 | Qutenza |
| Cognoa, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.